SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory Cancers.
HIF1
intra-tumor hypoxia
mTor
pediatric refractory cancers
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Oct 2020
20 Oct 2020
Historique:
received:
21
08
2020
revised:
09
10
2020
accepted:
09
10
2020
entrez:
23
10
2020
pubmed:
24
10
2020
medline:
24
10
2020
Statut:
epublish
Résumé
Hypoxic environment is a prognostic factor linked in pediatric cancers to a worse outcome, favoring tumor progression and resistance to treatments. The activation of mechanistic Target Of Rapamycin (mTor)/hypoxia inducible factor (HIF)-1 pathway can be targeted by rapamycin and irinotecan, respectively. Therefore, we designed a phase I trial associating both drugs in pediatric refractory/relapsing solid tumors. Patients were enrolled according to a 3 + 3 escalation design with ten levels, aiming to determine the MTD (maximum tolerated dose) of rapamycin plus irinotecan. Rapamycin was administered orally once daily in a 28-day cycle (1 to 2.5 mg/m
Identifiants
pubmed: 33092063
pii: cancers12103051
doi: 10.3390/cancers12103051
pmc: PMC7656302
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Institut National Du Cancer
ID : N° Eudract: 2010-022329-13
Références
J Clin Oncol. 2007 Oct 20;25(30):4722-9
pubmed: 17947719
J Neuroimaging. 2017 Jan;27(1):128-134
pubmed: 27079293
Toxicol Appl Pharmacol. 2014 Feb 1;274(3):471-9
pubmed: 24380837
Oncotarget. 2017 May 23;8(34):56698-56713
pubmed: 28915623
Oncogene. 2019 Sep;38(39):6585-6598
pubmed: 31444410
Eur J Cancer. 2012 Jan;48(2):253-62
pubmed: 22033322
Pediatr Blood Cancer. 2012 Mar;58(3):372-9
pubmed: 21509928
Nat Rev Cancer. 2004 May;4(5):335-48
pubmed: 15122205
Biochem Biophys Res Commun. 2015 Jun 5;461(3):560-7
pubmed: 25912138
J Clin Oncol. 2004 Apr 15;22(8):1382-8
pubmed: 15007088
Clin Cancer Res. 2014 Jun 15;20(12):3133-45
pubmed: 24727322
Clin Cancer Res. 2007 Apr 15;13(8):2441-8
pubmed: 17438103
Clin Pharmacokinet. 2018 Oct;57(10):1229-1254
pubmed: 29520731
J Clin Oncol. 2007 Oct 20;25(30):4806-12
pubmed: 17947729
Cell Tissue Res. 2018 May;372(2):269-275
pubmed: 29032465
Cancer Chemother Pharmacol. 2008 Nov;62(6):1027-37
pubmed: 18278496
Clin Cancer Res. 2013 Jul 1;19(13):3649-58
pubmed: 23659969
Cancer Metab. 2014 Feb 04;2(1):3
pubmed: 24491179
Cancer Res. 2006 Apr 15;66(8):4249-55
pubmed: 16618748
Cancer Res. 2005 Aug 15;65(16):7267-75
pubmed: 16103078
Pediatr Blood Cancer. 2006 Jan;46(1):50-5
pubmed: 15768380
Lancet Oncol. 2017 Jul;18(7):946-957
pubmed: 28549783
J Clin Oncol. 2011 Jul 20;29(21):2933-40
pubmed: 21690471
Oncologist. 2012;17(8):1063-72
pubmed: 22707516
Pediatr Blood Cancer. 2019 Mar;66(3):e27540
pubmed: 30393943
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
Pediatr Blood Cancer. 2015 Mar;62(3):440-4
pubmed: 25446280
Br J Cancer. 2003 Jun 16;88(12):1925-31
pubmed: 12799638
Oral Oncol. 2018 Feb;77:9-15
pubmed: 29362130
Cancer Res. 2000 Dec 15;60(24):6921-6
pubmed: 11156391
J Neurooncol. 2010 Sep;99(2):177-85
pubmed: 20066473
Acta Radiol. 2020 Jun 15;:284185120933219
pubmed: 32539423
Clin Orthop Relat Res. 2008 Sep;466(9):2052-9
pubmed: 18528739
Pediatr Blood Cancer. 2008 Apr;50(4):799-805
pubmed: 17635004
Nat Rev Cancer. 2011 Feb;11(2):85-95
pubmed: 21258394
Cancer Res. 2009 Mar 15;69(6):2663-8
pubmed: 19276368
Clin Pharmacol Ther. 1999 May;65(5):576-82
pubmed: 10340924
World J Gastroenterol. 2009 Sep 14;15(34):4278-83
pubmed: 19750570
Lancet Oncol. 2015 Jun;16(6):e270-8
pubmed: 26065612
Clin Radiol. 2015 Oct;70(10):1087-95
pubmed: 26231469
J Biol Chem. 2007 Jul 13;282(28):20534-43
pubmed: 17502379
J Clin Pharmacol. 2015 Nov;55(11):1303-12
pubmed: 25975718
Mol Cancer Ther. 2010 Jun;9(6):1755-63
pubmed: 20530716
Mol Med. 2012 Feb 10;18:83-94
pubmed: 22033674
Clin Cancer Res. 2009 Feb 15;15(4):1297-307
pubmed: 19190131
Clin Cancer Res. 2017 Oct 1;23(19):5769-5778
pubmed: 28679773
Pediatr Blood Cancer. 2014 May;61(5):833-9
pubmed: 24249672
J Clin Neurosci. 2006 Oct;13(8):811-7
pubmed: 16997706
Cancer Lett. 2010 Sep 1;295(1):100-9
pubmed: 20356670
Acta Neuropathol. 2005 Feb;109(2):211-6
pubmed: 15614581
Trends Cancer. 2016 Dec;2(12):758-770
pubmed: 28741521
Oncotarget. 2017 Mar 23;8(42):71597-71617
pubmed: 29069732